Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Formulary Focus: PCSK9 Drug Prices May Lead Payers To Impose Coverage Restrictions

Executive Summary

Anticipating annual pricing of up to $10,000 per patient for PCSK9 cholesterol-lowering drugs that will be prescribed for life, payers are taking a very close look at how to limit use to the patients who most need to take the drugs in the new class instead of low-cost statins.

You may also be interested in...



PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.

Any Medicare Study Requirements For Alzheimer’s Drugs Should Be Time Limited, CMS Told

Alliance for Aging Research worries the studies could drag on as long as the nine years Biogen is allowed for collecting Phase IV clinical data on its Aduhelm.

Interchangeable Biosimilars: Insulin Likely First But Humira May Be More Important Precedent

US FDA’s first decision on biosimilars interchangeability might have less meaning for two insulin products, but payer and prescriber responses to interchangeable biosimilars for adalimumab, which are further out on the horizon, may be more instructive regarding the importance of interchangeability status.

Topics

Related Companies

UsernamePublicRestriction

Register

PS056610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel